Introduction: Many active ingredients from natural plants (AINPs) have been revealed to possess remarkable anticancer properties. Combination chemotherapy of chemo-drugs and AINPs has also proven to be more advantageous than individual chemo-drug treatment with respect to enhancing efficiency, alleviating toxicity, and controlling the development of multidrug resistance (MDR). Co-delivery is considered a promising method to effectively achieve and manage combination chemotherapy of chemo-drugs and AINPs, and various distinctive and functional co-delivery systems have been designed for these purposes to date.Areas covered: This review focuses on recent preclinical investigations of co-delivery systems for chemo-drugs and AINPs as new cancer treatment modalities. We particularly emphasize the apparent treatment advantages of these approaches, including augmenting efficiency, reducing toxicity, and controlling MDR.Expert opinion: There has already been notable progress in the application of combination chemotherapy with co-delivery systems loaded with chemo-drugs and AINPs based on results with cellular and animal models. The main challenge is to translate these successes into new anticancer compound preparations and promote their clinical application in practice. Nevertheless, continuous efforts with new designs of co-delivery systems remain essential, providing a foundation for future clinical research and development of new anticancer drugs.

中文翻译：

---

天然植物化学药物和活性成分的共同递送系统：癌症治疗的临床前研究概述。

简介：已发现许多天然植物（AINPs）的活性成分具有出色的抗癌特性。化学药物和AINP的联合化学疗法在提高效率，减轻毒性和控制多药耐药性（MDR）方面也被证明比单独的化学药物治疗更具优势。共递送被认为是有效实现和管理化学药物和AINP联合化疗的一种有前途的方法，迄今为止，已针对这些目的设计了各种独特的功能性共递送系统。涵盖的领域：本综述着重于近期的临床前研究化学药物和AINPs的共同交付系统作为新的癌症治疗方式。我们特别强调这些方法在治疗上的明显优势，包括提高效率，降低毒性和控制MDR。专家意见：基于细胞和动物模型的结果，联合化疗联合载有化学药物和AINP的共同递送系统的应用已经取得了显着进展。主要挑战是将这些成功转化为新的抗癌化合物制剂，并在实践中促进其临床应用。然而，继续进行新的共同递送系统设计的努力仍然是必不可少的，这为新的抗癌药物的未来临床研究和开发奠定了基础。根据细胞和动物模型的结果，联合化疗联合载有化学药物和AINP的共同给药系统的应用已经取得了显着进展。主要挑战是将这些成功转化为新的抗癌化合物制剂，并在实践中促进其临床应用。然而，继续进行新的共同递送系统设计的努力仍然是必不可少的，这为新的抗癌药物的未来临床研究和开发奠定了基础。根据细胞和动物模型的结果，联合化疗联合载有化学药物和AINP的共同给药系统的应用已经取得了显着进展。主要挑战是将这些成功转化为新的抗癌化合物制剂，并在实践中促进其临床应用。然而，继续进行新的共同递送系统设计的努力仍然是必不可少的，这为新的抗癌药物的未来临床研究和开发奠定了基础。